ALPMF (ALPMF) Stock Price & Analysis
ALPMF (ALPMF) rose 7.62% to USD 14.26 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
ALPMF last closed at USD 13.25; the session ranged USD 14.26–14.26 on volume of 100 shares. Market capitalization is $25.55B, with a 52-week range of USD 9.34–17.85 (PNK). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 14.26 |
|---|---|
| Change | ▲ 7.62% (up) |
| Previous Close | USD 13.25 |
| Open | USD 14.26 |
| Day Range | USD 14.26 – 14.26 |
| 52-Week Range | USD 9.34 – 17.85 |
| Volume | 100 shares |
| Market Cap | $25.55B |
| Exchange | PNK |
Technical Analysis (ALPMF)
Nexqual's technical model rates ALPMF "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 48.33 (neutral) |
| vs SMA50 | Below (USD 15.24) |
| MACD | -0.26 (negative) |
Analyst Ratings (ALPMF)
Wall Street analysts rate ALPMF "None", per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | None |
|---|
Earnings (ALPMF)
| Next Earnings Date | 2026-04-27 |
|---|---|
| Revenue Estimate | $562.30B |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (ALPMF)
| Total Revenue | $2.14T |
|---|---|
| Revenue Growth (YoY) | +20.70% |
| Gross Margin | +80.91% |
| Operating Margin | +16.51% |
| Profit Margin | +13.63% |
| ROE | +17.44% |
| Debt / Equity | 30.91 |
| Current Ratio | 1.17 |
| Total Cash | $281.61B |
| Total Debt | $565.95B |
| Free Cash Flow | $388.72B |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (ALPMF)
Nexqual rates ALPMF's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Strong — Revenue +171% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 81%, operating 17% |
| Balance Sheet | Solid — $281.6B cash vs $566.0B debt |
| Cash Flow | Strong — FCF $388.7B, 18% margin |
| Efficiency | Solid — ROE 17%, ROA 6.9% |
Ownership (ALPMF)
| Insider Ownership | +0.11% |
|---|---|
| Institutional Ownership | +60.35% |
| Shares Outstanding | 1.79B |
| Float | 1.79B |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (ALPMF)
ALPMF is led by Naoki Okamura BSc (age 63), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| President, CEO & Director | Naoki Okamura BSc (age 63) |
|---|---|
| Executive VP, Chief People Officer & Representative Director | Katsuyoshi Sugita (age 58) |
| Senior Executive Officer & CFO | Atsushi Kitamura |
| Chief Scientific Officer & Senior Managing Executive Officer | Yoshitsugu Shitaka |
| President of Japan Commercial & Senior Corporate Executive | Nobuaki Tanaka |
Major Backers & Investors (ALPMF)
Notable institutional backers of ALPMF include Fidelity, J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF, AQR Funds-AQR Long-Short Equity Fund, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.68% |
| J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF | 0.29% |
| AQR Funds-AQR Long-Short Equity Fund | 0.29% |
| Pacer Advisors, Inc. | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.88% |
| BlackRock | 1.47% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALPMY | Astellas Pharma, Inc. | USD 13.3 | ▲ 0.53% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| TKPHF | Takeda Pharmaceutical Co., Ltd. | USD 32.6 | ▲ 6.99% |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22.85 | ▼ 0.91% |
| BAYZF | Bayer A.G. | USD 41.27 | ▼ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.